These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 28862476

  • 1. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH, Maran A, Robinson SI.
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM, Trinh VA, Posey K, Somaiah N.
    J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK.
    Lancet; 2016 Jul 30; 388(10043):488-97. PubMed ID: 27291997
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.
    Cancer Lett; 2019 Jun 01; 451():122-127. PubMed ID: 30867142
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
    Davis EJ, Chugh R.
    Drug Des Devel Ther; 2017 Jun 01; 11():3579-3587. PubMed ID: 29263653
    [Abstract] [Full Text] [Related]

  • 11. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue K, Oakley GJ, Sakaguchi S, Tamura K.
    Cancer Sci; 2018 Dec 01; 109(12):3962-3970. PubMed ID: 30353601
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL, ANNOUNCE Investigators.
    JAMA; 2020 Apr 07; 323(13):1266-1276. PubMed ID: 32259228
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G, Lee ATJ, Huang PH, Jones RL.
    Eur J Cancer; 2018 Mar 07; 92():33-39. PubMed ID: 29413687
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, Surguladze D, Loizos N, Luffer-Atlas D, Oakley GJ, Guo Q, Iyer S, Rubin BP, Stancato L.
    Clin Cancer Res; 2018 Feb 15; 24(4):847-857. PubMed ID: 29191969
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
    Jones RL, Mo G, Baldwin JR, Peterson PM, Ilaria RL, Conti I, Cronier DM, Tap WD.
    Cancer Chemother Pharmacol; 2019 Jan 15; 83(1):191-199. PubMed ID: 30406840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.